Benevolent Platform Precision Medicine slide image

Benevolent Platform Precision Medicine

Inhibition of Target A has antifibrotic effect in TGF-☐ activated primary human hepatic stellate cells Fibroblast to myofibroblast transition aSMA 150 Run 1 Mean +/- SD Collagen a-SMA/Col 1 mean cellular intensity TGF- HSCs, TGFb, 72h 1750- 1250 1000 1500- 1250- 1000- 750- 500- - 750 - 500 250 250- 0 0 0.01 0.1 1 10 TGF+ [ng/ml] Source: Company internal drug programme O Cells per well % inhibition % inhibition 100- 50- -50- -8 -7 -6 -5 Log Compound [M] 150 Run 2 Mean +/- SD 100 50- Nuceli Count α-SMA → Collagen I Tool compound Target A SPR KD 17nM Cell-based TE assay IC 50 5.4nM WLP >30-fold selectivity Kinome profiling >200-fold selectivity No effect on cell viability a-SMA Collagen 1 Nuclei Count RUN 1 (IC50) 9.5nM 7.OnM 2.3μM D -8 -7 -6 -5 RUN 2 9.6nM 5.3nM -50 Log Compound [M] (IC50) 1.4μM Benevolent 61 Al
View entire presentation